Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of August 2011. The document serves as an Initial Director's Interest Notice submitted to the Australian Securities Exchange (ASX) and furnished to the SEC. The filing discloses the appointment of Mr. Lawrence Gozlan as a director effective August 8, 2011.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director interests and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the appointment of a new director, Mr. Lawrence Gozlan, on August 8, 2011. The filing reports no material changes to financial positions or operations.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the requirements of ASX Listing Rule 3.19A.1 and Section 205G of the Corporations Act regarding the disclosure of director interests.
Investor Verification Checklist
- Verify the appointment date of Mr. Lawrence Gozlan as August 8, 2011.
- Confirm that Mr. Gozlan holds no registered securities in the company (Part 1 reports "Nil").
- Confirm that Mr. Gozlan has no relevant interests in securities where he is not the registered holder (Part 2 reports "Nil").
- Confirm that Mr. Gozlan has no interests in contracts with the company (Part 3 reports "Nil").
- Note that the registrant is Prana Biotechnology Limited, not Altery Therapeutics Ltd as indicated in the request metadata.